BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38665913)

  • 1. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
    Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
    Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
    Xiong B; Fu B; Wu Y; Gao F; Hou C
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer.
    Lee MW; Jeon SK; Paik WH; Yoon JH; Joo I; Lee JM; Lee SH
    J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):735-745. PubMed ID: 38332658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
    McManus HD; Zhang D; Schwartz FR; Wu Y; Infield J; Ho E; Armstrong AJ; George DJ; Kruse D; Gupta RT; Harrison MR
    Clin Genitourin Cancer; 2023 Dec; 21(6):e429-e437.e2. PubMed ID: 37271698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.
    Kim YY; Lee J; Jeong WK; Kim ST; Kim JH; Hong JY; Kang WK; Kim KM; Sohn I; Choi D
    Gastric Cancer; 2021 Mar; 24(2):457-466. PubMed ID: 32970267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors.
    Crombé A; Kind M; Toulmonde M; Italiano A; Cousin S
    Eur J Radiol; 2020 Dec; 133():109340. PubMed ID: 33091834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
    Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
    Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy.
    Li JH; Zhang XM; Bian XJ; Gu WJ; Wan FN; Dai B; Ye DW
    Asian J Androl; 2023; 25(4):520-527. PubMed ID: 36629156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study.
    Maurits JSF; Sedelaar JPM; Mulders PFA; Aben KKH; Kiemeney LALM; Vrieling A
    Clin Nutr; 2022 Jan; 41(1):131-143. PubMed ID: 34872047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Formica V; Morelli C; Patrikidou A; Murias C; Butt S; Nardecchia A; Lucchetti J; Renzi N; Shiu KK; Roselli M; Arkenau HT
    Target Oncol; 2020 Jun; 15(3):327-336. PubMed ID: 32449030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
    Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
    Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer.
    Nakano O; Kawai H; Kobayashi T; Kohisa J; Ikarashi S; Hayashi K; Yokoyama J; Terai S
    Cancer Med; 2021 Jul; 10(13):4291-4301. PubMed ID: 33993635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia.
    Han J; Tang M; Lu C; Shen L; She J; Wu G
    Clin Nutr; 2021 Sep; 40(9):5156-5161. PubMed ID: 34461589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.
    Ebadi M; Tandon P; Moctezuma-Velazquez C; Ghosh S; Baracos VE; Mazurak VC; Montano-Loza AJ
    J Hepatol; 2018 Sep; 69(3):608-616. PubMed ID: 29709682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer.
    Tang T; Xie L; Hu S; Tan L; Lei X; Luo X; Yang L; Yang M
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1800-1810. PubMed ID: 35297568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.